Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2013

Open Access 01-12-2013 | Review

Intensity modulated radiotherapy for sinonasal malignancies with a focus on optic pathway preservation

Authors: Alexander Chi, Nam P Nguyen, William Tse, Gill Sobremonte, Patrick Concannon, Angela Zhu

Published in: Journal of Hematology & Oncology | Issue 1/2013

Login to get access

Abstract

Purpose

To assess if intensity-modulated radiotherapy (IMRT) can possibly lead to improved local control and lower incidence of vision impairment/blindness in comparison to non-IMRT techniques when treating sinonasal malignancies; what is the most optimal dose constraints for the optic pathway; and the impact of different IMRT strategies on optic pathway sparing in this setting.

Methods and materials

A literature search in the PubMed databases was conducted in July, 2012.

Results

Clinical studies on IMRT and 2D/3D (2 dimensional/3 dimensional) RT for sinonasal malignancies suggest improved local control and lower incidence of severe vision impairment with IMRT in comparison to non-IMRT techniques. As observed in the non-IMRT studies, blindness due to disease progression may occur despite a lack of severe toxicity possibly due to the difficulty of controlling locally very advanced disease with a dose ≤ 70 Gy. Concurrent chemotherapy’s influence on the the risk of severe optic toxicity after radiotherapy is unclear. A maximum dose of ≤ 54 Gy with conventional fractionation to the optic pathway may decrease the risk of blindness. Increased magnitude of intensity modulation through increasing the number of segments, beams, and using a combination of coplanar and non-coplanar arrangements may help increase dose conformality and optic pathway sparing when IMRT is used.

Conclusion

IMRT optimized with appropriate strategies may be the treatment of choice for the most optimal local control and optic pathway sparing when treating sinonasal malignancy.
Literature
1.
go back to reference Dulguerov P, Jacobson MS, Allal AS: Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer. 2001, 92: 3012-3029.CrossRefPubMed Dulguerov P, Jacobson MS, Allal AS: Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer. 2001, 92: 3012-3029.CrossRefPubMed
2.
go back to reference Ang KK, Ahamad A, Garden AS: The nasal cavity and paranasal sinuses. Radiation Oncology: Rationale, Technique, Results. Edited by: Cox JD, Ang KK. 2010, Philadelphia: Mosby, Inc, 183-206. 9 Ang KK, Ahamad A, Garden AS: The nasal cavity and paranasal sinuses. Radiation Oncology: Rationale, Technique, Results. Edited by: Cox JD, Ang KK. 2010, Philadelphia: Mosby, Inc, 183-206. 9
3.
go back to reference Ogawa K, Toita T, Kakinohana Y: Postoperative radiotherapy for squamous cell carcinoma of the maxillary sinus: analysis of local control and late complications. Oncol Rep. 2001, 8: 315-319.PubMed Ogawa K, Toita T, Kakinohana Y: Postoperative radiotherapy for squamous cell carcinoma of the maxillary sinus: analysis of local control and late complications. Oncol Rep. 2001, 8: 315-319.PubMed
4.
go back to reference Tiwari R, Hardillo JA, Tobi H: Carcinoma of the ethmoid: results f treatment with conventional surgery and post-operative radiotherapy. Eur J Surg Oncol. 1999, 25: 401-405.CrossRefPubMed Tiwari R, Hardillo JA, Tobi H: Carcinoma of the ethmoid: results f treatment with conventional surgery and post-operative radiotherapy. Eur J Surg Oncol. 1999, 25: 401-405.CrossRefPubMed
5.
go back to reference Jiang GL, Tucker SL, Guttenberger R: Radiation-induced injury to the visual pathway. Radiother Oncol. 1994, 30: 17-25.CrossRefPubMed Jiang GL, Tucker SL, Guttenberger R: Radiation-induced injury to the visual pathway. Radiother Oncol. 1994, 30: 17-25.CrossRefPubMed
6.
go back to reference Logue JP, Slevin NJ: Carcinoma of the nasal cavity and paranasal sinuses: an analysis of radical radiotherapy. Clin Oncol. 1991, 3: 84-89.CrossRef Logue JP, Slevin NJ: Carcinoma of the nasal cavity and paranasal sinuses: an analysis of radical radiotherapy. Clin Oncol. 1991, 3: 84-89.CrossRef
7.
go back to reference Sakai S, Kubo T, Mori N: A study of the late effects of radiotherapy and operation on patients with maxillary cancer. A survey more than 10 years after initial treatment. Cancer. 1988, 62: 2114-2117.CrossRefPubMed Sakai S, Kubo T, Mori N: A study of the late effects of radiotherapy and operation on patients with maxillary cancer. A survey more than 10 years after initial treatment. Cancer. 1988, 62: 2114-2117.CrossRefPubMed
8.
go back to reference Olmi P, Cellai E, Chiavacci A: Paranasal sinuses and nasal cavity cancer: different radiotherapeutic options, results and late damages. Tumori. 1986, 72: 589-595.PubMed Olmi P, Cellai E, Chiavacci A: Paranasal sinuses and nasal cavity cancer: different radiotherapeutic options, results and late damages. Tumori. 1986, 72: 589-595.PubMed
9.
go back to reference Nakissa N, Rubin P, Strohl : Ocular and orbital complications following radiation therapy of paranasal sinus malignancies and review of literature. Cancer. 1983, 51: 980-986.CrossRefPubMed Nakissa N, Rubin P, Strohl : Ocular and orbital complications following radiation therapy of paranasal sinus malignancies and review of literature. Cancer. 1983, 51: 980-986.CrossRefPubMed
10.
go back to reference Homma A, Oridate N, Suzuki F: Superselective high-dose cisplatin with concomitant radiotherapy in patients with advanced cancer of the nasal cavity and paranasal sinuses: a single institution experience. Cancer. 2009, 115: 4705-4714.CrossRefPubMed Homma A, Oridate N, Suzuki F: Superselective high-dose cisplatin with concomitant radiotherapy in patients with advanced cancer of the nasal cavity and paranasal sinuses: a single institution experience. Cancer. 2009, 115: 4705-4714.CrossRefPubMed
11.
go back to reference Gabriele AM, Airoldi M, Garzaro M: Stage III-IV sinonasal and nasal cavity carcinoma treated with three-dimensional conformal radiotherapy. Tumori. 2008, 94: 320-326.PubMed Gabriele AM, Airoldi M, Garzaro M: Stage III-IV sinonasal and nasal cavity carcinoma treated with three-dimensional conformal radiotherapy. Tumori. 2008, 94: 320-326.PubMed
12.
go back to reference Pommier P, Ginestet C, Sunyach MP: Conformal radiotherapy for paranasal sinus and nasal cavity tumors: three-dimensional treatment planning and preliminary results in 40 patients. Int J Radiat Oncol Biol Phys. 2000, 48: 485-493.CrossRefPubMed Pommier P, Ginestet C, Sunyach MP: Conformal radiotherapy for paranasal sinus and nasal cavity tumors: three-dimensional treatment planning and preliminary results in 40 patients. Int J Radiat Oncol Biol Phys. 2000, 48: 485-493.CrossRefPubMed
13.
go back to reference Roa WH, Hazuka MB, Sandler HM: Results of primary and adjuvant CT-based 3-dimensional radiotherapy for malignant tumors of the paranasal sinuses. Int J Radiat Oncol Biol Phys. 1994, 28: 857-865.CrossRefPubMed Roa WH, Hazuka MB, Sandler HM: Results of primary and adjuvant CT-based 3-dimensional radiotherapy for malignant tumors of the paranasal sinuses. Int J Radiat Oncol Biol Phys. 1994, 28: 857-865.CrossRefPubMed
14.
go back to reference Jansen EP, Keus RB, Hilgers FJ: Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma?. Int J Radiat Oncol Biol Phys. 2000, 48: 27-35.CrossRefPubMed Jansen EP, Keus RB, Hilgers FJ: Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma?. Int J Radiat Oncol Biol Phys. 2000, 48: 27-35.CrossRefPubMed
15.
go back to reference Snyers A, Janssens GO, Twickler MB: Malignant tumors of the nasal cavity and paranasal sinuses: long-term outcome and morbidity with emphasis on hypothalamic-pituitary deficiency. Int J Radiat Oncol Biol Phys. 2009, 73: 1343-1351.CrossRefPubMed Snyers A, Janssens GO, Twickler MB: Malignant tumors of the nasal cavity and paranasal sinuses: long-term outcome and morbidity with emphasis on hypothalamic-pituitary deficiency. Int J Radiat Oncol Biol Phys. 2009, 73: 1343-1351.CrossRefPubMed
16.
go back to reference Porceddu S, Martin J, Shanker G: Paranasal sinus tumors: peter maccallum cancer institute experience. Head Neck. 2004, 26: 322-330.CrossRefPubMed Porceddu S, Martin J, Shanker G: Paranasal sinus tumors: peter maccallum cancer institute experience. Head Neck. 2004, 26: 322-330.CrossRefPubMed
17.
go back to reference Blanco AI, Chao KS, Ozyigit G: Carcinoma of paranasal sinuses: long-term outcomes with radiotherapy. Int J Radiat Oncol Biol Phys. 2004, 59: 51-58.CrossRefPubMed Blanco AI, Chao KS, Ozyigit G: Carcinoma of paranasal sinuses: long-term outcomes with radiotherapy. Int J Radiat Oncol Biol Phys. 2004, 59: 51-58.CrossRefPubMed
18.
go back to reference Hoppe BS, Nelson CJ, Gomez DR: Unresectable carcinoma of the paranasal sinuses: outcomes and toxicities. Int J Radiat Oncol Biol Phys. 2008, 72: 763-769.CrossRefPubMed Hoppe BS, Nelson CJ, Gomez DR: Unresectable carcinoma of the paranasal sinuses: outcomes and toxicities. Int J Radiat Oncol Biol Phys. 2008, 72: 763-769.CrossRefPubMed
19.
go back to reference Mendenhall WM, Amdur RJ, Morris CG: Carcinoma of the nasal cavity and paranasal sinuses. Laryngoscope. 2009, 119: 899-906.CrossRefPubMed Mendenhall WM, Amdur RJ, Morris CG: Carcinoma of the nasal cavity and paranasal sinuses. Laryngoscope. 2009, 119: 899-906.CrossRefPubMed
20.
go back to reference Claus F, De Gersem W, De Wagter C: An implementation strategy for IMRT of ethmoid sinus cancer with bilateral sparing of the optic pathways. Int J Radiat Oncol Biol Phys. 2001, 51: 318-331.CrossRefPubMed Claus F, De Gersem W, De Wagter C: An implementation strategy for IMRT of ethmoid sinus cancer with bilateral sparing of the optic pathways. Int J Radiat Oncol Biol Phys. 2001, 51: 318-331.CrossRefPubMed
21.
go back to reference Duthoy W, Boterberg T, Claus F: Postoperative intensity-modulated radiotherapy in sinonasal carcinoma: clinical results in 39 patients. Cancer. 2005, 104: 71-82.CrossRefPubMed Duthoy W, Boterberg T, Claus F: Postoperative intensity-modulated radiotherapy in sinonasal carcinoma: clinical results in 39 patients. Cancer. 2005, 104: 71-82.CrossRefPubMed
22.
go back to reference Madani I, Bonte K, Vakaet L: Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. Int J Radiat Oncol Biol Phys. 2009, 73: 424-432.CrossRefPubMed Madani I, Bonte K, Vakaet L: Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. Int J Radiat Oncol Biol Phys. 2009, 73: 424-432.CrossRefPubMed
23.
go back to reference Combs SE, Konkel S, Schulz-Ertner D: Intensity modulated radiotherapy (IMRT) in patients with carcinomas of the paranasal sinuses: clinical benefit for complex shaped target volumes. Radiat Oncol. 2006, 1: 23-PubMedCentralCrossRefPubMed Combs SE, Konkel S, Schulz-Ertner D: Intensity modulated radiotherapy (IMRT) in patients with carcinomas of the paranasal sinuses: clinical benefit for complex shaped target volumes. Radiat Oncol. 2006, 1: 23-PubMedCentralCrossRefPubMed
24.
go back to reference Daly ME, Chen AM, Kara Bucci M: Intensity-modulated radiation therapy for malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys. 2007, 67: 151-157.CrossRefPubMed Daly ME, Chen AM, Kara Bucci M: Intensity-modulated radiation therapy for malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys. 2007, 67: 151-157.CrossRefPubMed
25.
go back to reference Hoppe BS, Wolden SL, Zelefsky MJ: Postoperative intensity-modulated radiation therapy for cancers of the paranasal sinuses, nasal cavity, and lacrimal glands: technique, early outcomes, and toxicity. Head Neck. 2008, 30: 925-932.CrossRefPubMed Hoppe BS, Wolden SL, Zelefsky MJ: Postoperative intensity-modulated radiation therapy for cancers of the paranasal sinuses, nasal cavity, and lacrimal glands: technique, early outcomes, and toxicity. Head Neck. 2008, 30: 925-932.CrossRefPubMed
26.
go back to reference Wiegner EA, Daly ME, Murphy JD: Intensity-modulated radiotherapy for tumors of the nasal cavity and paranasal sinuses: Clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys. 2012, 83: 243-251.CrossRefPubMed Wiegner EA, Daly ME, Murphy JD: Intensity-modulated radiotherapy for tumors of the nasal cavity and paranasal sinuses: Clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys. 2012, 83: 243-251.CrossRefPubMed
27.
go back to reference Dirix P, Vanstraelen B, Jorissen M: Intensity-modulated radiotherapy for sinonasal cancer: improved outcome compared to conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2010, 78: 998-1004.CrossRefPubMed Dirix P, Vanstraelen B, Jorissen M: Intensity-modulated radiotherapy for sinonasal cancer: improved outcome compared to conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2010, 78: 998-1004.CrossRefPubMed
28.
go back to reference Al-Mamgani A, Monserez D, Rooij PV: Highly-conformal intensity-modulated radiotherapy reduced toxicity without jeopardizing outcome in patients with paranasal sinus cancer treated by surgery and radiotherapy or (chemo) radiation. Oral Oncol. 2012, In press Al-Mamgani A, Monserez D, Rooij PV: Highly-conformal intensity-modulated radiotherapy reduced toxicity without jeopardizing outcome in patients with paranasal sinus cancer treated by surgery and radiotherapy or (chemo) radiation. Oral Oncol. 2012, In press
29.
go back to reference Chen AM, Daly ME, Kara Bucci M: Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement?. Int J Radiat Oncol Biol Phys. 2007, 69: 141-147.CrossRefPubMed Chen AM, Daly ME, Kara Bucci M: Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement?. Int J Radiat Oncol Biol Phys. 2007, 69: 141-147.CrossRefPubMed
30.
go back to reference Adams EJ, Nutting CM, Convery DJ: Potential role of intensity-modulated radiotherapy in the treatment of tumors of the maxillary sinus. Int J Radiat Oncol Biol Phys. 2001, 51: 579-588.CrossRefPubMed Adams EJ, Nutting CM, Convery DJ: Potential role of intensity-modulated radiotherapy in the treatment of tumors of the maxillary sinus. Int J Radiat Oncol Biol Phys. 2001, 51: 579-588.CrossRefPubMed
31.
go back to reference Lee SW, Kim GE, Suh CO: Intensity modulation technique using the complementary boost-fields for ethmoid sinus cancer. Clin Oncol. 2002, 14: 241-249.CrossRef Lee SW, Kim GE, Suh CO: Intensity modulation technique using the complementary boost-fields for ethmoid sinus cancer. Clin Oncol. 2002, 14: 241-249.CrossRef
32.
go back to reference O’Daniel JC, Dong L, Kuban DA: The delivery of IMRT with a single physical modulator for multiple fields: a feasibility study for paranasal sinus cancer. Int J Radiat Oncol Biol Phys. 2004, 58: 876-887.CrossRefPubMed O’Daniel JC, Dong L, Kuban DA: The delivery of IMRT with a single physical modulator for multiple fields: a feasibility study for paranasal sinus cancer. Int J Radiat Oncol Biol Phys. 2004, 58: 876-887.CrossRefPubMed
33.
go back to reference Huang D, Xia P, Akazawa P: Comparison of treatment plans using intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys. 2003, 56: 158-168.CrossRefPubMed Huang D, Xia P, Akazawa P: Comparison of treatment plans using intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys. 2003, 56: 158-168.CrossRefPubMed
34.
go back to reference Mock U, Georg D, Bogner J: Treatment planning comparison of conventional, 3D conformal, and intensity-modulated photon (IMRT) and proton therapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys. 2004, 58: 147-154.CrossRefPubMed Mock U, Georg D, Bogner J: Treatment planning comparison of conventional, 3D conformal, and intensity-modulated photon (IMRT) and proton therapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys. 2004, 58: 147-154.CrossRefPubMed
35.
go back to reference Pacholke HD, Amdur RJ, Louis DA: The role of intensity modulated radiation therapy for favorable stage tumor of the nasal cavity or ethmoid sinus. Am J Clin Oncol. 2005, 28: 474-478.CrossRefPubMed Pacholke HD, Amdur RJ, Louis DA: The role of intensity modulated radiation therapy for favorable stage tumor of the nasal cavity or ethmoid sinus. Am J Clin Oncol. 2005, 28: 474-478.CrossRefPubMed
36.
go back to reference Claus F, Mijnheer B, Rasch C: Report of a study on IMRT planning strategies for ethmoid sinus cancer. Strahlenther Onkol. 2002, 178: 572-576.CrossRefPubMed Claus F, Mijnheer B, Rasch C: Report of a study on IMRT planning strategies for ethmoid sinus cancer. Strahlenther Onkol. 2002, 178: 572-576.CrossRefPubMed
37.
go back to reference Wang X, Zhang X, Dong L: Effectiveness of noncoplanar IMRT planning using a parallelized multiresolution beam angle optimization method for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys. 2005, 63: 594-601.CrossRefPubMed Wang X, Zhang X, Dong L: Effectiveness of noncoplanar IMRT planning using a parallelized multiresolution beam angle optimization method for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys. 2005, 63: 594-601.CrossRefPubMed
38.
go back to reference Serre A, Idri K, Fenoglietto P: Dosimetric comparison between coplanar and non coplanar field radiotherapy for ethmoid sinus cancer. Radiat Oncol. 2007, 2: 35-PubMedCentralCrossRefPubMed Serre A, Idri K, Fenoglietto P: Dosimetric comparison between coplanar and non coplanar field radiotherapy for ethmoid sinus cancer. Radiat Oncol. 2007, 2: 35-PubMedCentralCrossRefPubMed
39.
go back to reference Sheng K, Molloy JA, Larner JM: A dosimetric comparison of non-coplanar IMRT versus helical tomotherapy for nasal cavity and paranasal sinus cancer. Radiother Oncol. 2007, 82: 174-178.CrossRefPubMed Sheng K, Molloy JA, Larner JM: A dosimetric comparison of non-coplanar IMRT versus helical tomotherapy for nasal cavity and paranasal sinus cancer. Radiother Oncol. 2007, 82: 174-178.CrossRefPubMed
40.
go back to reference Chen AM, Sreeraman R, Mathai M, Vijayakumar S, Purdy JA: Potential of helical tomotherapy to reduce dose to the ocular structures for patients treated for unresectable sinonasal cancer. Am J Clin Oncol. 2010, 33: 595-598.CrossRefPubMed Chen AM, Sreeraman R, Mathai M, Vijayakumar S, Purdy JA: Potential of helical tomotherapy to reduce dose to the ocular structures for patients treated for unresectable sinonasal cancer. Am J Clin Oncol. 2010, 33: 595-598.CrossRefPubMed
41.
go back to reference Tsien C, Eisbruch A, McShan D: Intensity-modulated radiation therapy (IMRT) for locally advanced paranasal sinus tumors: incorporating clinical decisions in the optimization process. Int J Radiat Oncol Biol Phys. 2003, 55: 776-784.CrossRefPubMed Tsien C, Eisbruch A, McShan D: Intensity-modulated radiation therapy (IMRT) for locally advanced paranasal sinus tumors: incorporating clinical decisions in the optimization process. Int J Radiat Oncol Biol Phys. 2003, 55: 776-784.CrossRefPubMed
42.
go back to reference Elbaz H, Stueckle T, Tse W: Digitoxin and its analogs as novel cancer therapeutics. Ex Hematol Oncol. 2012, 1: 4-CrossRef Elbaz H, Stueckle T, Tse W: Digitoxin and its analogs as novel cancer therapeutics. Ex Hematol Oncol. 2012, 1: 4-CrossRef
43.
go back to reference Weiβ L, Efferth T: Polo-like kinase 1 as target for cancer therapy. Exp Hematol Oncol. 2012, 1: 38-CrossRef Weiβ L, Efferth T: Polo-like kinase 1 as target for cancer therapy. Exp Hematol Oncol. 2012, 1: 38-CrossRef
44.
45.
go back to reference Rafiyath SM, Rasul M, Lee B: Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines; a meta-analysis. Exp Hematol Oncol. 2012, 1: 10-PubMedCentralCrossRefPubMed Rafiyath SM, Rasul M, Lee B: Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines; a meta-analysis. Exp Hematol Oncol. 2012, 1: 10-PubMedCentralCrossRefPubMed
46.
go back to reference Mayo C, Martel MK, Marks LB: Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys. 2010, 76 (3 Suppl): S28-S35.CrossRefPubMed Mayo C, Martel MK, Marks LB: Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys. 2010, 76 (3 Suppl): S28-S35.CrossRefPubMed
47.
go back to reference Martel MK, Sandler HM, Cornblath WT: Dose-volume complication analysis for visual pathway structures of patients with advanced paranasal sinus tumors. Int J Radiat Oncol Biol Phys. 1997, 38: 273-284.CrossRefPubMed Martel MK, Sandler HM, Cornblath WT: Dose-volume complication analysis for visual pathway structures of patients with advanced paranasal sinus tumors. Int J Radiat Oncol Biol Phys. 1997, 38: 273-284.CrossRefPubMed
48.
go back to reference Chi A, Jang SY, Welsh JS: Feasibility of helical tomotherapy in stereotactic body radiation therapy for centrally located early stage non-small-cell lung cancer or lung metastases. Int J Radiat Oncol Biol Phys. 2011, 81: 856-862.CrossRefPubMed Chi A, Jang SY, Welsh JS: Feasibility of helical tomotherapy in stereotactic body radiation therapy for centrally located early stage non-small-cell lung cancer or lung metastases. Int J Radiat Oncol Biol Phys. 2011, 81: 856-862.CrossRefPubMed
Metadata
Title
Intensity modulated radiotherapy for sinonasal malignancies with a focus on optic pathway preservation
Authors
Alexander Chi
Nam P Nguyen
William Tse
Gill Sobremonte
Patrick Concannon
Angela Zhu
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2013
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-6-4

Other articles of this Issue 1/2013

Journal of Hematology & Oncology 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine